Phase 3 Trial

Cortexyme Inc (NASDAQ: CRTX) has presented additional data from its Phase 2/3 GAIN Trial at the Clinical Trials on Alzheimer's Disease Conference.  The 643-participant 48-week GAIN Trial failed to meet statistical significance on its co-primary cognitive and...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced histology and biomarkers analysis results from the Ongoing Open-Label Part of the ARMOR Phase 3 study of Aramchol in NASH and liver fibrosis stage 1 3 patients.  Galmed previously announced a substantial effect on ...

GlaxoSmithKline plc (NYSE: GSK) announced positive results from the ASCEND program comprised of five Phase 3 studies assessing daprodustat for anemia due to chronic kidney disease (CKD). Daprodustat is an investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (...

Bristol Myers Squibb & Co (NYSE: BMY) has announced topline data from Phase 3 CheckMate -816 trial in patients with resectable stage IB to IIIA non-small cell lung cancer (NSCLC).  The trial evaluated Opdivo (nivolumab) plus chemotherapy compared to chemotherapy alone as...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced additional results from a Phase 3 trial, which assessed a single dose of REGEN-COV (1,200 mg administered via 4 subcutaneous injections) to prevent COVID-19 in uninfected individuals.  The new analyses show REGEN-COV...

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal tumor (GIST) previously treated with Novartis AG's (NYSE: NVS) Gleevec (...

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) announced results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled post-baseline biopsy.  ARMOR is assessing the evaluate the safety and efficacy of Aramchol for the treatment of...

Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) announced results from the Phase 3 trial comparing TV-46000/mdc-IRM once monthly (q1m) and TV-46000/mdc-IRM once every two months (q2m) with placebo for schizophrenia patients who underwent stabilization on oral risperidone. ...

Merck & Co Inc (NYSE: MRK) announced new data from studies evaluating Keytruda (pembrolizumab) in melanoma patients.  The Company shared the data at the Society for Melanoma Research (SMR) 2021 Congress.  210 former participants of KEYNOTE-006 (158 patients treated...

AbbVie Inc (NYSE: ABBV) has announced topline results from two Phase 3 trials, Study 3111-301-001 and Study 3111-302-001, of cariprazine (Vraylar) as an adjunctive treatment for major depressive disorder (MDD).  In Study 3111-301-001, cariprazine showed a statistically significant...

Rafael Holdings Inc's (NYSE: RFL) Rafael Pharmaceuticals Inc announced that the AVENGER 500 Phase 3 trial for CPI-613 (devimistat) did not meet its primary endpoint of significant improvement in overall survival in pancreatic cancer patients. Data from 528 patients...

AstraZeneca Plc (NASDAQ: AZN) revealed topline results from the Phase 3 TOPAZ-1 study. Related: AstraZeneca Touts Longest Survival Update In Lung Cancer Setting With Imfinzi/Chemo Data. According to the data, a combo of Imfinzi (durvalumab) and chemotherapy significantly...

The Menarini Group and Radius Health Inc (NASDAQ: RDUS) have announced topline results from the EMERALD Phase 3 study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients. There were two primary endpoints...

ObsEva SA (NASDAQ: OBSV) has announced data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for uterine fibroids. The data were presented at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo. Related: ObsEva Files US Application For...

ImmunityBio Inc (NASDAQ: IBRX) has announced that Papillary disease (Cohort B) of its Phase 2/3 study of intravesical BCG plus Anktiva met its primary endpoints with disease-free survival of 57% at 12 months.  Non-muscle invasive bladder cancer (NMIBC) makes up 75%-85% of all...